Deep Dive - MINT: opportunities in ‘frontier’ markets?
Published in Pharmaphorum’s Deep Dive magazine October 2017
According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are the countries he believes are poised for strong economic growth, like the emerging markets of BRIC (Brazil, Russia, India and China) before them. What are the prospects for pharma in MINT? Research Partnership’s Rachel Howard and Sue Rees investigate the pros and cons.
Ageing Asia: What does the future hold?
Published in eyeforpharma September 2017 by Marc Yates
Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population, contributing to declining fertility and increasing life expectancy. However, in turn, such changing demographic features are set to have profound repercussions on the continent’s socio-economic and healthcare set-up in the coming decades.
Global health care specialists from coast to coast
Published in Quirk's Faces of Marketing Research August 2017
Research Partnership is celebrating 20 years in business this year with expansion across the U.S., opening new offices in San Francisco and New York. With headquarters in Philadelphia and a satellite office in Boston, Research Partnership is now expertly placed to support pharma from West to East coast. We shine a light on four of our key faces of research.
Navigating South Korea’s Healthcare Paradox
Published in eyeforpharma August 2017 by Marc Yates
In recent years, we have witnessed an explosion of interest among our pharmaceutical clients in conducting research in South Korea. Some emerging market analysts have suggested a ‘K’ should be added to BRIC, reflecting the country’s burgeoning economic status and its increasingly inclusion in global studies, not just regional Asia Pacific or emerging market studies. Indeed, there is ongoing debate about whether South Korea can still be considered ‘emerging’ as it is a growing player in the pharmaceutical industry in its own right.
As well as looking at South Korea’s healthcare outlook in more detail, in this article we also ask why the country lies at the extremes of two conflicting global health indicators – longest life expectancy and highest suicide rates.
Living with Lupus: Breaking the Silence
Published in eyeforpharma July 2017 by Mariel Metcalfe
Lupus is an almost invisible disease, yet can have considerable impact on patients’ quality of life, but there is much that pharma can do to help.